BioSpace News Archive

Daxor Corporation(NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA.

Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the third quarter ended September 30, 2019

Agilent Technologies Inc. (NYSE: A) has announced that the nomination process to submit proposals to receive an Agilent-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Jaffray 31st Annual Healthcare Conference in New York City on Thursday, December 5, 2019 at 11:50 a.m. ET / 8:50 a.m. PT.

Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year

MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia

Anchored in a nationwide network of leading health systems, Excelera’s new pharmacy benefit solution uniquely aligns pharmacy benefit management across the stakeholder continuum [21-November-2019] MINNEAPOLIS , Nov. 21, 2019 /PRNewswire/ -- Excelera ® , the company behind the Excelera Network, a nationwide network of leading health systems and academic medical cente

Vizient announced it has signed an agreement with Fresenius Kabi to supply six critical care drugs under Vizient’s successful Novaplus private label pharmacy program.

Aerie Pharmaceuticals, Inc. announced the European Commission has granted a marketing authorisation for Rhokiinsa® 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City.